Infant with rare epilepsy receives intracerebral WWOX gene replacement, with no seizures during early follow-up

For infants with severe genetic epilepsy, time is often not an abstract concept, but the pressure of every seizure and every period of developmental regression. Israel’s Clalit-Schneider Children’s Medical Center recently reported that an infant with WOREE syndrome received an experimental WWOX gene replacement therapy, in which physicians used a neurosurgical procedure to deliver a functional gene copy directly into the brain; according to reports, no recurrence of epilepsy was seen within one month after treatment, and the infant has been discharged in stable condition.

WOREE syndrome, fully known as WWOX-related epileptic encephalopathy, is a rare neurodevelopmental disease caused by defects in the WWOX gene. Affected children may develop hard-to-control epilepsy, developmental delay or regression shortly after birth, and the prognosis is usually severe. The baby boy was reportedly healthy in appearance at birth, began to have severe epilepsy at about 6 weeks of age, and later genetic testing confirmed an association with a WWOX gene defect.

The core of this treatment is to replace a working copy of the WWOX gene. Reports indicate that the relevant technical foundation came from research by Professor Rami I. Aqeilan of the Hebrew University and colleagues. Early animal studies had shown that a single gene replacement could restore WWOX expression and improve indicators including epilepsy, abnormal growth, neurological deficits and survival. The therapy was later licensed to the U.S. biotechnology company Mahzi Therapeutics before gradually moving toward clinical case attempts.

Unlike many treatments administered intravenously or into the spinal canal, this procedure uses direct intracerebral injection, meaning it is not only an experiment in molecular medicine, but also a highly precise neurosurgical intervention. Reports say that before treatment, regulatory and ethics approvals from multiple countries had to be obtained, and the dose had to be calculated according to the infant’s condition; these details show that it currently remains a highly customized compassionate or experimental medical intervention, not a standard therapy.

The early results are notable, but they cannot be equated with a cure. Publicly available information still shows a short follow-up period, and only a single infant case has been reported so far; whether epilepsy can remain controlled over the long term, whether neurological development can recover or improve, how long gene expression can be maintained, and whether delayed safety risks may emerge all require longer follow-up and validation in more cases.

There are few known cases of WOREE syndrome worldwide, with reports estimating about 60 to 90 cases, and noting that it is relatively common among people of Yemenite Jewish ancestry. Treatment development for rare diseases often faces the same dilemma: too few patients, disease courses that move too quickly, and clinical trials that are difficult to conduct at traditional scale; but precisely because of this, case-based innovation sometimes becomes the first step forward in medicine.

This infant’s case opens a narrow door for the treatment of genetic epilepsy: if a disease originates from the loss of function of a single gene, restoring a functional gene is conceptually attractive. However, between one successful procedure and stable adoption by medical systems lie multiple hurdles, including manufacturing quality, delivery route, long-term safety, efficacy measures and equitable access. At this stage, the most cautious statement is that this is an early clinical attempt worthy of serious follow-up, not a conclusion that the treatment of rare neurological diseases has already been rewritten.